News

November 30, 2020November 30, 2020

IGC Starts Phase 1 Study of Low-dose Cannabinoid in Alzheimer’s Patients

News

A Phase 1 trial is enrolling patients with mild to severe dementia from Alzheimer’s disease to test IGC-AD1, an investigational cannabis-based treatment being developed India Globalization Capital (IGC) Pharma, ... Read more

November 25, 2020November 25, 2020

AlzeCure’s Lead Therapy Candidate Entering Phase 1 Testing in Sweden

News

AlzeCure Pharma is preparing to launch a Phase 1 clinical trial in Sweden to evaluate the tolerability and safety of ACD856, one of its therapy candidates for Alzheimer’s disease, ... Read more

November 23, 2020November 23, 2020

Gum Disease Bacteria Found in Most Alzheimer’s Patients in Atuzaginstat Trial

News

Most of the mild to moderate Alzheimer’s patients enrolled in the atuzaginstat (COR388) Phase 2/3 trial show evidence of systemic infection due to Porphyromonas gingivalis, a bacteria linked to periodontal disease whose toxic enzymes ... Read more

November 18, 2020November 18, 2020

Last Participant Finishes PEGASUS Clinical Trial, Results Expected Next Year

News

The last participant has completed the planned 24 weeks in the Phase 2 PEGASUS clinical trial, which is assessing the safety and biological activity of Amylyx Pharmaceuticals‘ investigational therapy ... Read more

November 16, 2020November 16, 2020

FDA Clears Neuraly to Begin Phase 2 Trial of NLY01 in Alzheimer’s Patients

News

The U.S. Food and Drug Administration has given clearance for a Phase 2B clinical trial to evaluate the safety, tolerability, and efficacy of Nueraly‘s investigational therapy NLY01 in people ... Read more

November 11, 2020November 11, 2020

FDA Committee Votes Do Not Support Aducanumab as Effective Treatment

News

An advisory arm of the U.S. Food and Drug Administration (FDA) is recommending that available clinical data on aducanumab (BIIB037) does not support the effectiveness of this investigational therapy ... Read more

November 9, 2020November 9, 2020

EMA Agrees to Review Biogen, Eisai Request for Aducanumab’s Approval

News

The European Medicines Agency (EMA) has agreed to review Biogen and Eisai’s application requesting the approval of aducanumab (BIIB037) for the treatment of Alzheimer’s disease. The companies’ approval request — ... Read more

November 4, 2020November 4, 2020

Awareness Month Activities Shine Spotlight on Alzheimer’s, Dementia

News

Efforts are underway this month to focus attention on Alzheimer’s, a disease that, along with other forms of dementia, affects some 44 million people globally and is swiftly growing in ... Read more

November 2, 2020November 2, 2020

Seth Rogen’s HFC ‘Game Show’ Raises $325K to Benefit Alzheimer’s Care

News

Using levity to battle a serious disease, entertainer Seth Rogen and his wife raised more than $325,000 for HFC, the couple’s national Alzheimer’s disease organization, during its first virtual game show. The ... Read more

October 28, 2020October 28, 2020

First Patient Dosed in Biomarker Study of Oral Alzheimer’s Therapy, ALZ-801

News

A first patient has been dosed in a Phase 2 trial evaluating the effects of ALZ-801 on disease-related biomarkers in people with early Alzheimer’s disease, who have a specific ... Read more